Metraipolis › archive › dc_2ef8455a0079
CT radiomics for differentiating fat poor angiomyolipoma from clear cell renal cell carcinoma: Systematic review and meta-analysis — Europe PMC PMID:37498830
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/37498830
- DOI
- 10.1371/journal.pone.0287299
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T14:05:37.197Z
- SHA-256 of the archived text
9a3e864bb0e0ceae392660cf46ba89cceaf4325dc172d5dbd90513e0a5140682- Stable URL of this page
https://metraipolis.com/documento/dc_2ef8455a0079
How to cite
CT radiomics for differentiating fat poor angiomyolipoma from clear cell renal cell carcinoma: Systematic review and meta-analysis — Europe PMC PMID:37498830 — Europe PMC (en), https://europepmc.org/article/MED/37498830 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_2ef8455a0079 (Metraipolis archive dc_2ef8455a0079, sha256 9a3e864bb0e0ceae392660cf46ba89cceaf4325dc172d5dbd90513e0a5140682)
BibTeX
@misc{dc2ef8455a0079,
title = {CT radiomics for differentiating fat poor angiomyolipoma from clear cell renal cell carcinoma: Systematic review and meta-analysis — Europe PMC PMID:37498830},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/37498830},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_2ef8455a0079; sha256 9a3e864bb0e0ceae392660cf46ba89cceaf4325dc172d5dbd90513e0a5140682},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/37498830. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Purpose: Differentiation of fat-poor angiomyolipoma (fp-AMLs) from renal cell carcinoma (RCC) is often not possible from just visual interpretation of conventional cross-sectional imaging, typically requiring biopsy or surgery for diagnostic confirmation. However, radiomics has the potential to characterize renal masses without the need for invasive procedures. Here, we conducted a systematic review on the accuracy of CT radiomics in distinguishing fp-AMLs from RCCs. Methods: We conducted a search using PubMed/MEDLINE, Google Scholar, Cochrane Library, Embase, and Web of Science for studies published from January 2011-2022 that utilized CT radiomics to discriminate between fp-AMLs and RCCs. A random-effects model was applied for the meta-analysis according to the heterogeneity level. Furthermore, subgroup analyses (group 1: RCCs vs. fp-AML, and group 2: ccRCC vs. fp-AML), and quality assessment were also conducted to explore the possible effect of interstudy differences. To evaluate CT radiomics performance, the pooled sensitivity, specificity, and diagnostic odds ratio (DOR) were assessed. This study is registered with PROSPERO (CRD42022311034). Results: Our literature search identified 10 studies with 1456 lesions in 1437 patients. Pooled sensitivity was 0.779 [95% CI: 0.562-0.907] and 0.817 [95% CI: 0.663-0.910] for groups 1 and 2, respectively. Pooled specificity was 0.933 [95% CI: 0.814-0.978]and 0.926 [95% CI: 0.854-0.964] for groups 1 and 2, respectively. Also, our findings showed higher sensitivity and specificity of 0.858 [95% CI: 0.742-0.927] and 0.886 [95% CI: 0.819-0.930] for detecting ccRCC from fp-AML in the unenhanced phase of CT scan as compared to the corticomedullary and nephrogenic phases of CT scan. Conclusion: This study suggested that radiomic features derived from CT has high sensitivity and specificity in differentiating RCCs vs. fp-AML, particularly in detecting ccRCCs vs. fp-AML. Also, an unenhanced CT scan showed the highest specificity and sensitivity as compared to contrast CT scan phases. Differentiating between fp-AML and RCC often is not possible without biopsy or surgery; radiomics has the potential to obviate these invasive procedures due to its high diagnostic accuracy. Tema degli esploratori: matematica e informatica teorica (ricerca Europe PMC «number theory», solo open access). Pubblicazione: PloS one, 2023 (prima pubblicazione 2023-07-27). Identificativi: PMID 37498830 · PMCID PMC10374097 · DOI 10.1371/journal.pone.0287299. Descrittori MeSH principali: Angiomyolipoma; Carcinoma, Renal Cell; Kidney Neoplasms; Leukemia, Myeloid, Acute. Pagina: https://europepmc.org/article/MED/37498830 — https://doi.org/10.1371/journal.pone.0287299. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T12:24:06.070Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.